Também conhecido como
Total PSA
Free PSA
Complexed PSA
Nome formal
Prostate Specific Antigen
Este artigo foi revisto pela última vez em
Este artigo foi modificado pela última vez em
18 de Abril de 2018.
At a Glance
Why Get Tested?
To screen asymptomatic and symptomatic men for prostate cancer, to help determine the necessity for a biopsy of the prostate, to monitor the effectiveness of treatment for prostate cancer, and to detect recurrence of prostate cancer; there is currently no consensus about using PSA tests to screen for prostate cancer.
When To Get Tested?
When a man has symptoms suggestive of prostate cancer such as difficult, painful, and/or frequent urination; may also be ordered during and at regular intervals after prostate cancer treatment. There is continued debate among experts and national organizations over when and how often to order the PSA test to screen asymptomatic men. The frequency of prostate cancer screening is an individual decision that should be determined through discussion with your physician. (For specific details, see prostate cancer screening for adults and adults 50 and up).
Sample Required?
A blood sample drawn from a vein in the arm
Test Preparation Needed?
None, but keep in mind that the sample should be collected prior to your doctor performing a digital rectal exam (DRE) and prior to (or several weeks after) a prostate biopsy.
What is being tested?
PSA is a protein produced primarily by cells in the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Most of the PSA that the prostate produces is released into this fluid, but small amounts of it are also released into the bloodstream. PSA exists in two forms in the blood: free (not bound) and complexed (cPSA, bound to a protein). The most frequently used PSA test is the total PSA, which measures the sum of the free PSA and the cPSA in the blood. When a doctor orders a “PSA test,” he is referring to a total PSA.

This test is used as a tumor marker to screen for and to monitor prostate cancer. It is a good tool but not a perfect one, and currently there is no consensus among experts on the usefulness of this test for screening asymptomatic men. Elevated levels of PSA are associated with prostate cancer, but they may also be seen with prostatitis and benign prostatic hyperplasia (BPH). Mild to moderately increased concentrations of PSA may be seen in those of African American heritage, and levels tend to increase in all men as they age.

PSA is not diagnostic of cancer. The gold standard for identifying prostate cancer is the prostate biopsy, collecting small samples of prostate tissue and identifying abnormal cells under the microscope. The total PSA test and digital rectal exam (DRE) are used together to help determine the need for a prostate biopsy. The goal of screening is to minimize unnecessary biopsies and to detect clinically significant prostate cancer while it is still confined to the prostate. The term clinically significant is important because while prostate cancer becomes relatively common in men as they age, many of the tumors are very slow-growing and this type of cancer is an uncommon cause of death. Doctors must try to both detect prostate cancer and to differentiate between slow-growing cases and prostate cancers that may grow aggressively and spread to other parts of the body (metastasize). Over-diagnosing and over-treatment are issues with which doctors are currently grappling. In some cases, the treatment can be worse than the cancer, with the potential for causing significant side effects, incontinence, and erectile dysfunction. The PSA test and DRE can detect most cases of prostate cancer, but they cannot, in general, predict the course of a person’s disease.

Free PSA and cPSA tests can be ordered individually. The tests that measure them were developed to better differentiate between cancer-related and non-cancer-related PSA increases. Both of the tests operate on the principle that men with prostate cancer frequently have altered ratios of the two forms of PSA - decreased amounts of free PSA and increased amounts of cPSA.

How is the sample collected for testing?

A blood sample is taken by needle from a vein in the arm.

Is any test preparation needed to ensure the quality of the sample?

The sample should be collected prior to the physician performing a digital rectal exam (DRE) and prior to (or several weeks after) a prostate biopsy.
Accordion Title
Common Questions
  • How is it used?
    If prostate cancer is diagnosed, the total PSA test may be used as a monitoring tool to help determine the effectiveness of treatment. It may also be ordered at regular intervals after treatment to detect recurrence of the cancer.

    The total PSA test and digital rectal exam (DRE) may be used to screen both asymptomatic and symptomatic men for prostate cancer. If either the PSA or the DRE are found to be abnormal, then the doctor may choose to follow this testing with a prostate biopsy and perhaps imaging tests, such as an ultrasound. If the DRE is normal but the PSA is moderately elevated, the doctor may order a free PSA test to look at the ratio of free to total PSA. This can help to distinguish between prostate cancer and other non-cancer causes of elevated PSA. Since the total PSA test can be elevated temporarily for a variety of reasons, a doctor may order another PSA a few weeks after the first to determine if the PSA is still elevated.

    Currently there is no consensus about using the PSA test to screen for prostate cancer in asymptomatic men. While prostate cancer is a relatively common type of cancer in men, it is an uncommon cause of death. In cases where the cancer appears to be slow-growing, the doctor and patient may decide to monitor its progress rather than pursue immediate treatment (called "watchful waiting"). Total PSA levels may be ordered at frequent intervals to monitor the change in PSA over time.

    The complexed PSA (cPSA) is a relatively new test that may be ordered, along with the DRE, as an alternative to the total PSA. There is hope that this test could be more specific than the total PSA - better at detecting cancer-related PSA, but findings have been mixed and its ultimate clinical utility has yet to be established. The cPSA is an option that doctors can discuss with their patients. Its use may expand and/or be better defined as additional studies are conducted and findings are reported.

  • When is it ordered?
    There is currently no consensus among the experts about when the PSA test should be ordered to screen asymptomatic males. Over-diagnosing, identifying cases of prostate cancer that may never cause significant health problems, must be balanced against missing the detection of aggressive cancers. There are national organizations, such as the National Cancer Institute and Centers for Disease Control and Prevention, that do not recommend routine screening at this time. Others, such as the American Cancer Society (ACS), recommend that doctors offer total PSA tests and DRE annually to all men, beginning at age 50 and to those at an increased risk of prostate cancer, such as American men of African descent and men with a family history of the disease, beginning at age 40 or 45. The ACS recommends that doctors discuss the testing options, benefits, and potential side effects with their male patients so that they can make informed choices. (See Prostate Cancer Screening for Adults and Adults 50 and Up.)

    The total PSA test and DRE may also be ordered when a man has symptoms that could be due to prostate cancer, such as difficult, painful, and/or frequent urination, back pain, and/or pelvic pain. Since these symptoms are seen with a variety of other conditions, including infection and prostatitis, the doctor will also frequently order other tests, such as a urine culture. Some of these conditions can themselves cause temporary increases in PSA levels. If a total PSA level is elevated, a doctor may order a repeat test a few weeks later to determine whether the PSA concentrations have returned to normal.

    A free PSA is primarily ordered when a man has a moderately elevated total PSA. The results give the doctor additional information about whether ther person is at an increased risk of having prostate cancer and help with the decision of whether to biopsy the prostate.

    The total PSA may be ordered during treatment of men who have been diagnosed with prostate cancer to verify the effectiveness of treatment and at regular intervals after treatment to monitor for cancer recurrence. It is also ordered at regular intervals when a man with cancer is participating in “watchful waiting” and not currently treating his prostate cancer.

  • What does the test result mean?
    PSA test results can be interpreted a number of different ways and there may be differences in cutoff values between different laboratories. The normal value for total PSA is considered to be less than 4.0 ng/ml (nanograms per milliliter of blood). There are some that feel that this level should be lowered to 2.5 ng/ml in order to detect more cases of prostate cancer. Others argue that this would exacerbate over-diagnosing and over-treating cancers that are not clinically significant.

    There is agreement that men with a total PSA level greater than 10.0 ng/ml are at an increased risk for prostate cancer (more than a 67% chance, according to the ACS). Levels between 4.0 ng/ml and 10.0 ng/ml may indicate prostate cancer (about a 25% chance, according to the ACS), BPH, or prostatitis. These conditions are more common in the elderly, as is a general increase in PSA levels. Concentrations of total PSA between 4.0 ng/ml and 10.0 ng/ml are often referred to as the “gray zone.” It is in this range that the free PSA is the most useful. When men in the gray zone have decreased levels of free PSA, they have a higher probability of prostate cancer; when they have elevated levels of free PSA, the risk is diminished. The ratio of free to total PSA can help the doctor decide whether or not a prostate biopsy should be performed.

    When the complexed PSA (cPSA) test is used as a screening tool, increased levels may indicate an increased risk of prostate cancer, while lower levels indicate a decreased risk.

    In addition to the introduction of the free PSA and cPSA tests, there have been efforts to increase the usefulness of the total PSA as a screening tool. They include:

    • PSA velocity. This is the change in PSA concentrations over time. If the PSA continues to rise significantly over time (such as 3 or more years), then it is more likely that prostate cancer is present. If it climbs rapidly, then the affected person may have a more aggressive form of cancer.
    • PSA doubling time. This is another version of the PSA velocity. It measures how rapidly the PSA concentration doubles.
    • PSA density. This is a comparison of the PSA concentration and the volume of the prostate (as measured by ultrasound). Men with larger prostates tend to produce more PSA, so this factor is an adjustment to compensate for the size.
    • Age-specific PSA ranges. Since PSA levels naturally increase as a man ages, it has been proposed that normal ranges be tailored to a man's age.

    During treatment for prostate cancer, the PSA level should begin to fall. At the end of treatment, it should be at very low or undetectable levels in the blood. If concentrations do not fall to very low levels, then the treatment has not been fully effective. Following treatment, the PSA test is performed at regular intervals to monitor the person for cancer recurrence. Since even tiny increases can be significant, those affected may want to have their monitoring PSA tests done by the same laboratory each time so that testing variation is kept to a minimum.

    A relatively new test called "ultrasensitive PSA" (USPSA) has been reported. It has been suggested that this test may be useful in monitoring for persistence or recurrence of cancer after treatment. This test detects PSA at much lower levels than the traditional test. It has been suggested that increases in PSA due to the persistence or return of cancer can be identified much sooner with this test. However, results of this test must be interpreted with caution. Because the test is very sensitive, there can be an increase in PSA levels from one time to the next even when no cancer is present (false positive).

  • Is there anything else I should know?
    Since the DRE can cause a temporary elevation in PSA, the blood is usually collected prior to performing the DRE.

    Prostate manipulation by biopsy or resection of the prostate will significantly elevate PSA levels. The blood test should be done before surgery or six weeks after manipulation.

    Rigorous physical activity affecting the prostate, such as bicycle riding, may cause a temporary rise in PSA levels. Large doses of some chemotherapeutic drugs, such as cyclophosphamide and methotrexate, may increase or decrease PSA levels.

    In some men, PSA may rise temporarily due to other prostate conditions, especially infection. A recent study found that in about half of men with a high PSA, values later return to normal. Some authorities recommend that a high PSA should be repeated, between 6 weeks and 3 months after the high PSA, before taking any further action. Some physicians will prescribe a course of antibiotics if there is evidence that there is infection of the prostate.

  • If I have prostate cancer, what are my options?
    The most common treatments include radiation, hormone therapy, and surgery. For more information, see Prostate Cancer and the Links associated with this article.
  • Will PSA testing detect all prostate cancers?
    No. Sometimes cancer cells do not produce much PSA, and the test will be negative even when the disease is present.
View Sources
Sources Used in Current Review

Pagana, K. D. & Pagana, T. J. (© 2007). Mosby’s Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 772-774.

Clarke, W. and Dufour, D. R., Editors (© 2006). Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. Pp 243, 246.

Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 906-913.

(2008 November 20). What you need to know about Prostate Cancer. National Cancer Institute [On-line information]. Available online at http://www.cancer.gov/cancertopics/wyntk/prostate through http://www.cancer.gov. Accessed March 2009.

(© 2009). Detailed Guide: Prostate Cancer. American Cancer Society [On-line information]. Available online at http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?rnav=cridg&dt=36 through http://www.cancer.org. Accessed March 2009.

(2009 March 19). PSA Testing: What Should Men Do? Fallout from 2 studies, pro and con, has experts in a quandary. MedlinePlus HealthDay [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/news/fullstory_81937.html through http://www.nlm.nih.gov. Accessed March 2009.

Morse Linn, M. et al (Posted 2008 January 9). Prostate-Specific Antigen Screening: Friend or Foe? Emedicine from Urol Nurs. 2007;27(6):481-489. [On-line information]. Available online at http://www.medscape.com/viewarticle/568053 through http://www.medscape.com. Accessed March 2009.

Chustecka, Z. News and Lie, D. CME (Released 2008 August 5). USPSTF Recommends Against Prostate Cancer Screening in Men 75 Years or Older. CME/CE Medscape Medical News, Online CME [On-line information]. Available online at http://www.medscape.com/viewarticle/578591 through http://www.medscape.com. Accessed March 2009.

Michael, A. et al (Posted 2009 March 6). Prostate Cancer Chemotherapy in the Era of Targeted Therapy. Medscape from Prostate Cancer Prostatic Dis. 2009;12(1):13-16. [On-line information]. Available online at http://www.medscape.com/viewarticle/589071 through http://www.medscape.com. Accessed March 2009.

Melanie Ketchandji, M. et al (Posted 2009 February 5). Cause of Death in Older Men After the Diagnosis of Prostate Cancer. Medscape from J Am Geriatr Soc. 2009;57(1):24-30. Available online at http://www.medscape.com/viewarticle/586741 through http://www.medscape.com. Accessed March 2009.

(Reviewed 2009 March 18). Prostate-Specific Antigen (PSA) Test. NCI Fact Sheet [On-line information]. Available online at http://www.cancer.gov/cancertopics/factsheet/Detection/PSA through http://www.cancer.gov. Accessed March 2009.

Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER and Bruns DE, eds. 4th ed. St. Louis, Missouri: Elsevier Saunders; 2006, Pg 761.

(July 30, 2009) American Cancer Society. Following PSA Levels After Treatment Meant to Cure Prostate Cancer. Available online at http://www.cancer.org/docroot/CRI/content/CRI_2_4_4X_Following_PSA_levels_36.asp?sitearea= through http://www.cancer.org. Accessed August 2009.

McDermed J. Using PSA Intelligently to Manage Prostate Cancer. Part 2 of 2. PCRI Insights. August, 2005. Vol. 8, no. 3. Available online at http://www.prostate-cancer.org/education/preclin/McDermed_Using_PSA_Intelligently2.html through http://www.prostate-cancer.org. Accessed November 2009.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber’s Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby’s Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Ballentine Carter, H., et. al. (2204 September 22). Report to the Nation on Prostate Cancer 2004, Chapter 1: Detection, Diagnosis, and Prognosis of Prostate Cancer CME. Medscape Today, Clinical Update [On-line CME]. Available online at http://www.medscape.com/viewprogram/3440?src=sidesearch through http://www.medscape.com.

(2005 January 1, Revised). Detailed Guide: Prostate Cancer, Can Prostate Cancer Be Found Early? American Cancer Society [On-line information]. Available online through http://www.cancer.org.

(2004 August 17, Reviewed). The Prostate-Specific Antigen (PSA) Test: Questions and Answers. National Cancer Institute, Cancer Facts [On-line information]. Available online at http://cis.nci.nih.gov/fact/5_29.htm through http://cis.nci.nih.gov.

(2004 May 26). Some Men with Low PSAs Have Prostate Cancer: Most Cancers Found Are Not Likely to Be Clinically Significant. NIH News [On-line Press Release]. Available online at http://www.nih.gov/news/pr/may2004/nci-26.htm through http://www.nih.gov.

(© 1995 – 2004). Benign Prostatic Hyperplasia. Merck Manual [On-line information]. Available online through http://www.merck.com.

(2003 March, Reviewed). Benign Prostatic Hyperplasia (BPH). Familydoctor.org [[On-line information]. Available online at http://familydoctor.org/148.xml through http://familydoctor.org.

(2003 August, Reviewed). American Urological Association. Benign Prostatic Hyperplasia (BPH), A Patient’s Guide. Available online through http://www.urologyhealth.org.